AbbVie’s Dividend Still Has Cover, but Apogee Adds Leverage

AbbVie raised its quarterly dividend 5.5% as Skyrizi and Rinvoq offset Humira’s decline. The $10.9 billion Apogee acquisition strengthens the pipeline but adds debt and near-term dilution.
AbbVie’s dividend is growing faster than many large pharmaceutical payouts, but investors are receiving a lower yield after a strong share-price run. The company now pays $1.73 per share each quarter, up from $1.64 in 2025. That 5.5% increase lifts the annualized payout to $6.92.
At a share price of $285.40 cited in the source article, the forward yield was about 2.4%. The yield fell because the stock had gained 28.6% for the year, not because the dividend was cut. For an income investor, that distinction matters: the cash payment increased, while the price paid for each dollar of income rose.
Coverage remains reasonable on management’s adjusted figures. AbbVie guided to 2026 adjusted earnings of $13.87 to $14.07 per share. Using the midpoint, the annual dividend consumes about 49.5% of adjusted earnings. Free cash flow also exceeded the cash needed for the payout in the source analysis. GAAP earnings are less useful for this comparison because acquired research and development charges can make the trailing price-to-earnings ratio look unusually high.
The operating support comes from Skyrizi and Rinvoq. In the second quarter, Humira revenue fell 35.9% to $756 million, while Skyrizi rose 24.4% to $5.51 billion and Rinvoq increased 24.5% to $2.53 billion. Together, the two newer immunology drugs generated about $8.03 billion. Imbruvica remained a weak point, with revenue down 29.4%.
AbbVie’s agreement to acquire Apogee Therapeutics for about $10.9 billion could deepen the immunology pipeline, but it changes the balance-sheet calculation. The company expects the transaction to reduce 2026 adjusted earnings by $0.14 per share and plans to finance it with cash and debt. AbbVie already carried net debt of roughly 2.26 times EBITDA in the source analysis.
The dividend is not under immediate pressure based on current adjusted earnings and cash flow. The next test is whether Skyrizi and Rinvoq keep replacing Humira’s lost sales while management absorbs Apogee without allowing leverage or development spending to crowd out future increases.
Continue your APGE research
Related News
Bank OZK's Rising Dividend Is Well Covered, but Credit Still Sets the Limit
Bank OZK raised its quarterly dividend for a 65th straight quarter. A payout near one-third of earnings provides room, while construction-loan credit remains the main constraint.
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Parabilis Heads Into ESMO With Strong Early Data and a High Bar
Parabilis will present updated zolucatetide data in desmoid tumors on Oct. 24. Early responses were strong, but investors still need durability, safety and a credible Phase 3 dose.
Pfizer's 5.8% Yield Depends on Cash Flow Catching Up
Pfizer's dividend remains covered by adjusted earnings, but 2025 free cash flow fell short of distributions. Debt and patent expirations leave management less room to restore dividend growth.
Three Stocks Hit New Lows, but the Risks Were Very Different
EyePoint, CoreWeave and Eos Energy touched new lows on the same day. The selloffs reflected three distinct problems: a failed pivotal trial, financing pressure and manufacturing execution risk.















Latest comments